Recent Updates
Recently added Catalysts

ACYC

Phase 3

Acne | Small molecule | Dermatology |Bausch Health Companies Inc.|Last Updated: Jun 4, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment498
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01701024Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe AcnePHASE3 COMPLETED 498 — — Oct 1, 2012Jul 1, 2013Jun 4, 201824 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Absolute Change in Inflammatory Lesion Count
Baseline and 12 Weeks
Absolute Change in Non-inflammatory Lesion Count
Baseline and 12 Weeks
Percent of Subjects Who Have a Least a 2 Grade Reduction
Baseline and 12 Weeks
Percent of Subjects With Two Grade Reduction From Baseline and Achieving Clear or Almost Clear
Baseline and 12 Weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ACYCACTIVE_COMPARATORACYC active, topically applied to the face for 12 weeks
ACYC vehiclePLACEBO_COMPARATORACYC vehicle (placebo), topically applied to the face for 12 weeks
Interventions
NameTypeDescription
ACYCDRUGACYC active, topically applied to the face for 12 weeks
ACYC vehicleDRUGACYC vehicle (placebo), topically applied to the face for 12 weeks
Unlock Study Design Details
Eligibility Criteria
Age Range12 Years — 40 Years
SexALL
Healthy VolunteersNo
Study Sites24

Key Inclusion Criteria: * Male or female between the ages of 12 and 40 (inclusive) * Written and verbal informed consent must be obtained. * Subjects less than 18 years of age must sign an assent for the study and a parent or a legal guardian must sign the informed consent * Subject must have moder...

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Acne 12 trials
CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV1PHASE3Undisclosed
Biofrontera, Inc.BFRI1PHASE21h Incubation Photodynamic therapy, 3h Incubation Photodynamic therapy
Sanofi SA Sponsored ADRSNY3PHASE1Acne mRNA vaccine
Hoth Therapeutics, Inc.HOTH1PHASE2HT-001 2%, HT-001 1%, HT-001 0.5%
Sagimet Biosciences Inc. Class ASGMT1PHASE1TVB-3567
Bausch Health Companies Inc.BHC1 — clindamycin , adapalene and benzoyl peroxide
Unlock Competitive Intelligence